[URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].

Q4 Medicine
Acta Medica Croatica Pub Date : 2016-12-01
M Butković
{"title":"[URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].","authors":"M Butković","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Although asymptomatic hyperuricemia is rather often in laboratory reports, it cannot be considered a disease. Despite the\nhigh prevalence of hyperuricemia in patients with arterial hypertension (AH), chronic kidney disease (CKD), cardiovascular\ndisease (CVD) or metabolic syndrome, hyperuricemia is not confirmed as a causative factor of these disorders. The aim is\nto point to the latest studies of the importance of urate as a possible cardiorenal risk factor. The literature published in 2015\nand 2016 was searched for the possible impact of urate level on the development of cardiorenal diseases. The PubMed,\nCochrane, Medline, and UpToDate databases were searched for the literature published between November 2009 and\nOctober 2016 using the following key words: urate, hyperuricemia, cardiovascular disease, and chronic kidney disease.\nCausative correlation of hyperuricemia is confirmed only in disorders where deposits of monosodium urate crystals are\npresent. Results of recent studies do not justify routine use of xanthine oxidase inhibitors in asymptomatic hyperuricemia.\nSome studies with small numbers of patients and short follow up report on endothelial function improvement on therapy\nwith xanthine oxidase inhibitors. Nonpharmacological intervention by changing unhealthy lifestyle is preferred. Treatment\nof asymptomatic hyperuricemia in CKD is still debated, and additional studies are necessary to demonstrate the benefit\nof lowering urate level in CKD. Family doctors (general practitioners) should be familiar with the recommended approach\nto patients with asymptomatic hyperuricemia. Evidence based medicine still does not recommend target determination\nof serum urate level for identifying CVD and CKD risk factors. Recent studies suggest the possible effect of uric acid in\ncardiorenal diseases and that treatment of asymptomatic hyperuricemia with xanthine oxidase inhibitors may also be\nuseful in CVD prevention. Additional studies are needed to prove this statement.</p>","PeriodicalId":35756,"journal":{"name":"Acta Medica Croatica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Croatica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Although asymptomatic hyperuricemia is rather often in laboratory reports, it cannot be considered a disease. Despite the high prevalence of hyperuricemia in patients with arterial hypertension (AH), chronic kidney disease (CKD), cardiovascular disease (CVD) or metabolic syndrome, hyperuricemia is not confirmed as a causative factor of these disorders. The aim is to point to the latest studies of the importance of urate as a possible cardiorenal risk factor. The literature published in 2015 and 2016 was searched for the possible impact of urate level on the development of cardiorenal diseases. The PubMed, Cochrane, Medline, and UpToDate databases were searched for the literature published between November 2009 and October 2016 using the following key words: urate, hyperuricemia, cardiovascular disease, and chronic kidney disease. Causative correlation of hyperuricemia is confirmed only in disorders where deposits of monosodium urate crystals are present. Results of recent studies do not justify routine use of xanthine oxidase inhibitors in asymptomatic hyperuricemia. Some studies with small numbers of patients and short follow up report on endothelial function improvement on therapy with xanthine oxidase inhibitors. Nonpharmacological intervention by changing unhealthy lifestyle is preferred. Treatment of asymptomatic hyperuricemia in CKD is still debated, and additional studies are necessary to demonstrate the benefit of lowering urate level in CKD. Family doctors (general practitioners) should be familiar with the recommended approach to patients with asymptomatic hyperuricemia. Evidence based medicine still does not recommend target determination of serum urate level for identifying CVD and CKD risk factors. Recent studies suggest the possible effect of uric acid in cardiorenal diseases and that treatment of asymptomatic hyperuricemia with xanthine oxidase inhibitors may also be useful in CVD prevention. Additional studies are needed to prove this statement.

[尿酸是心血管和肾脏疾病的潜在危险因素]。
虽然无症状高尿酸血症在实验室报告中相当常见,但它不能被认为是一种疾病。尽管高尿酸血症在动脉高血压(AH)、慢性肾病(CKD)、心血管疾病(CVD)或代谢综合征患者中患病率很高,但高尿酸血症并未被证实是这些疾病的致病因素。其目的是指出尿酸作为一种可能的心肾危险因素的重要性的最新研究。检索2015年和2016年发表的文献,寻找尿酸水平对心肾疾病发展的可能影响。检索PubMed、Cochrane、Medline和UpToDate数据库,检索2009年11月至2016年10月间发表的文献,检索关键词:尿酸、高尿酸血症、心血管疾病和慢性肾脏疾病。高尿酸血症的病因相关性仅在有尿酸钠结晶沉积的疾病中得到证实。最近的研究结果不证明常规使用黄嘌呤氧化酶抑制剂治疗无症状高尿酸血症是合理的。一些少量患者和短随访的研究报告了黄嘌呤氧化酶抑制剂治疗后内皮功能的改善。通过改变不健康的生活方式进行非药物干预是首选。CKD无症状高尿酸血症的治疗仍存在争议,需要进一步的研究来证明降低CKD尿酸水平的益处。家庭医生(全科医生)应该熟悉无症状高尿酸血症患者的推荐治疗方法。循证医学仍然不推荐用血清尿酸水平作为确定CVD和CKD危险因素的指标。最近的研究表明尿酸对心肾疾病的可能影响,并且用黄嘌呤氧化酶抑制剂治疗无症状高尿酸血症也可能有助于预防心血管疾病。需要进一步的研究来证明这一说法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Medica Croatica
Acta Medica Croatica Medicine-Medicine (all)
自引率
0.00%
发文量
0
期刊介绍: ACTA MEDICA CROATICA publishes original contributions to medical sciences, that have not been previously published. All manuscripts should be written in English.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信